C4 Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||
| Balance as of December 31, 2023 | 60,467,188 | $6 | $774,618 | $(127) | $(528,383) | $246,114 | ||||
| Issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 5,567,928 | 1 | 19,999 | — | — | 20,000 | ||||
| Issuance of common stock pursuant to the at-the-market equity program, net | 4,132,122 | — | 24,370 | — | — | 24,370 | ||||
| Exercise of stock options and release of stock units | 149,818 | — | 778 | — | — | 778 | ||||
| Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 176,819 | — | (194) | — | — | (194) | ||||
| Issuance of common stock under the 2020 ESPP | 110,895 | — | 382 | — | — | 382 | ||||
| Stock-based compensation | — | — | 29,662 | — | — | 29,662 | ||||
| Unrealized gain on marketable securities | — | — | — | 180 | — | 180 | ||||
| Net loss | — | — | — | — | (105,316) | (105,316) | ||||
| Other | 21,129 | — | 10 | — | — | 10 | ||||
| Balance as of December 31, 2024 | 70,625,899 | $7 | $849,625 | $53 | $(633,699) | $215,986 | ||||
| Issuance of common stock pursuant to the underwritten offering, net | 21,895,000 | 2 | 116,867 | — | — | 116,869 | ||||
| Issuance of common stock pursuant to the at-the-market equity program, net | 3,769,483 | 9,340 | — | — | 9,340 | |||||
| Exercise of stock options and release of stock units | 50,000 | 107 | — | — | 107 | |||||
| Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 349,766 | (193) | — | — | (193) | |||||
| Issuance of common stock under the 2020 ESPP | 170,703 | 273 | — | — | 273 | |||||
| Stock-based compensation | — | 19,099 | — | — | 19,099 | |||||
| Unrealized gain on marketable securities | — | — | (3) | — | (3) | |||||
| Net loss | — | — | — | (104,994) | (104,994) | |||||
| Other | 53,567 | 103 | — | — | 103 | |||||
| Balance as of December 31, 2025 | 96,914,418 | $9 | $995,221 | $50 | $(738,693) | $256,587 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.